$320.23
$309.25
$354.31
$171.37
$6.9B
52.31%
This is a preview of the full version of Prosperse
Madrigal Pharmaceuticals, a mid-cap biotech company, has gained FDA approval for its NASH therapy Rezdiffra, making it a potential leader in the field. However, the company faces challenges, including the need to produce positive efficacy data in confirmatory trials and competition from larger pharm...
Prosper Junior Bakiny
Aug 17, 2024
Madrigal Pharmaceuticals, a biopharmaceutical company focused on NASH, announced the appointment of Shannon Kelley as their new General Counsel. Kelley has over 20 years of healthcare experience and previously held roles at Sanofi and Boston Scientific.
N/A
Aug 2, 2024
Date: Nov 19, 2024
Date: Nov 19, 2024
Date: Nov 14, 2024
Date: Nov 14, 2024
Date: Nov 14, 2024